Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BriaCell Therapeutics Corp. entered into Master Service and Technology Agreement with Prevail InfoWorks, Inc. valued at $5,379,945 (effective 2023-05-09).
- Action
- entry
- Counterparty
- Prevail InfoWorks, Inc.
- Value
- $5,379,945
- Effective
- 2023-05-09
Exact text from the filing
On May 9, 2023, BriaCell Therapeutics Corp. (the “Company”) entered into a Master Service and Technology Agreement (the “MST Agreement”) with Prevail InfoWorks, Inc. (“InfoWorks”) pursuant to which InfoWorks will provide clinical services and technologies for the Company’s upcoming pivotal study in advanced metastatic breast cancer.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BriaCell Therapeutics Corp. entered into Stock Purchase Agreement with Prevail Partners, LLC valued at $4,000,000 (effective 2023-05-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Prevail Partners, LLC
- Value
- $4,000,000
- Effective
- 2023-05-12
Exact text from the filing
On May 12, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, pursuant to which the Company agreed to issue 463,408 common shares (the “Shares”) for an aggregate purchase price of $4,000,000.
View on SEC.gov